基于因子分析法的16家中药上市公司成长性评价实证研究

An empirical study on growth evaluation of 16 Chinese materia medica listed companies based on factor analysis

运用因子分析法,选取2014年16家中药上市公司的8个财务指标,建立中药上市公司成长性综合评价体系,对16家中药上市公司成长性进行综合评价。结果表明,16家中药上市公司之间的规模、成长性差异显著,整体成长性表现有待提高。在规模能力、盈利能力、成长能力方面,吉林敖东(得分29.492)、白云山(得分31.809)、通化东宝(得分42.110)分别位列第一位。成长性最好的是白云山(得分31.089),最差的是太极集团(得分-7.053)。应从加大科研开发的投入,增强创新力度,提高中药上市公司创新能力;加强优势资源整合,优化产品结构,实现中药上市公司规模化和可持续化发展;树立品牌意识,加强内部管理,增强中药上市公司的市场竞争力等方面进一步提升和优化我国中药上市公司的成长性。

Eight financial indicators of 16 listed companies of Chinese materia medica（CMM） in 2014 were selected by factor analysis method. A comprehensive growth evaluation system was established, so as to make an empirical research on growth evaluation among 16 CMM listed companies. Results show： Sixteen CMM listed companies＇ scale and growth differences among the companies is significant, and overall growth performance should be improved. On the aspect of scale ability, profitability, and growth ability, Jilin Aodong Medicine Industry Group Co., Ltd.（score 29.492）, Guangzhou Baiyun Mountain Pharmaceutical Co., Ltd（Baiyun Mountain）（score 31.809）, Dongbao Pharmaceutical Co., Ltd.（score 42.110） separately ranked first. The best growth is Baiyun Mountain（score 31.089）, and the worst is Taiji Group Co., Ltd.（score-7.053）. Some suggestions should be put forward： Increase research and investment, enhance innovation, improve the management ability of CMM listed companies; Strengthen the integration of advantageous resources and optimize the structure of products, realizing the scaled and sustained development of CMM listed companies; Establish brand awareness and strengthen internal management, so as to enhance the market competitiveness of CMM listed companies, etc.